[go: up one dir, main page]

AU2001253618A1 - Flavopiridol drug combinations and methods with reduced side effects - Google Patents

Flavopiridol drug combinations and methods with reduced side effects

Info

Publication number
AU2001253618A1
AU2001253618A1 AU2001253618A AU5361801A AU2001253618A1 AU 2001253618 A1 AU2001253618 A1 AU 2001253618A1 AU 2001253618 A AU2001253618 A AU 2001253618A AU 5361801 A AU5361801 A AU 5361801A AU 2001253618 A1 AU2001253618 A1 AU 2001253618A1
Authority
AU
Australia
Prior art keywords
flavopiridol
methods
side effects
drug combinations
reduced side
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253618A
Inventor
Federico Innocenti
Lalitha Iyer
Mark J Ratain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of AU2001253618A1 publication Critical patent/AU2001253618A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001253618A 2000-04-21 2001-04-12 Flavopiridol drug combinations and methods with reduced side effects Abandoned AU2001253618A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55382900A 2000-04-21 2000-04-21
US09/553,829 2000-04-21
US09553829 2000-04-21
PCT/US2001/012526 WO2001080896A2 (en) 2000-04-21 2001-04-12 Flavopiridol drug combinations and methods with reduced side effects

Publications (1)

Publication Number Publication Date
AU2001253618A1 true AU2001253618A1 (en) 2001-11-07

Family

ID=24210919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253618A Abandoned AU2001253618A1 (en) 2000-04-21 2001-04-12 Flavopiridol drug combinations and methods with reduced side effects

Country Status (3)

Country Link
US (1) US20020016293A1 (en)
AU (1) AU2001253618A1 (en)
WO (1) WO2001080896A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082099A1 (en) * 1999-05-01 2001-11-01 The Court Of Napier University Method of analysis of medical signals
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
WO2003039537A1 (en) * 2001-11-05 2003-05-15 Alla Shapiro Chemoprotectant compositions
GB0201607D0 (en) * 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
WO2004027088A2 (en) * 2002-09-20 2004-04-01 UNIVERSITé LAVAL Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug
US20040265323A1 (en) * 2003-05-16 2004-12-30 Mccormick Beth A. Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
KR20070048645A (en) * 2004-03-01 2007-05-09 더 유니버시티 오브 시카고 Polymorphism in Epidermal Growth Factor Receptor Gene Promoter
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2005087952A1 (en) * 2004-03-05 2005-09-22 The Regents Of The University Of California Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants
CA2571683A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US9044474B2 (en) * 2010-11-08 2015-06-02 The Ohio State University Compositions and methods for increasing drug efficacy in cancer
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US20140309974A1 (en) * 2013-04-15 2014-10-16 The Regents Of The University Of California Optimization of input parameters of a complex system based on multiple criteria
US20160186263A1 (en) 2013-05-09 2016-06-30 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
SE538241C2 (en) * 2014-05-07 2016-04-12 Xylem Ip Man Sarl Guide tube assembly and guide tube holder therefore
RU2752729C2 (en) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Prodrugs of alvocidib having high bioavailability
JP7083497B2 (en) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド Combination therapy for the treatment of cancer
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10195214B2 (en) 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
CN113490499A (en) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer
MX2021005075A (en) * 2018-12-07 2021-07-15 Sumitomo Pharma Oncology Inc Methods for treating castration-resistant and castration- sensitive prostate cancer.
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
US20230035479A1 (en) * 2019-09-20 2023-02-02 President And Fellows Of Harvard College Methods and compositions for reducing hair greying
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN115697337A (en) 2020-05-27 2023-02-03 科赛普特治疗学股份有限公司 Concurrent administration of glucocorticoid receptor modulators, rilacolan and paclitaxel (dual substrates for CYP2C8 and CYP3 A4)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744676A1 (en) * 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Combination product for cancer therapy

Also Published As

Publication number Publication date
US20020016293A1 (en) 2002-02-07
WO2001080896A3 (en) 2002-07-11
WO2001080896A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001253618A1 (en) Flavopiridol drug combinations and methods with reduced side effects
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
AU2001275441A1 (en) Filter arrangement and methods
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU5532499A (en) Moveable and sectional block toy
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU2001280599A1 (en) Compounds and methods
AU7065200A (en) Putting improvement devices and methods
AU2001253418A1 (en) Compounds and methods
AU2001287023A1 (en) Plasma-derived-fibrin-based matrices and tissue
AU715620C (en) Therapeutic methods and uses
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2002211717A1 (en) Stresscopins and their uses
AUPP995799A0 (en) Improvements in hinges
AU2001243394A1 (en) Compounds and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002243386A1 (en) Rf2a and rf2b transcription factors
AU1745400A (en) Sorting apparatuses and sorting methods
AU7458201A (en) Laminate and use thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2001296673A1 (en) Mountable and removable sensor
AU2001229439A1 (en) Bioconjugates and uses thereof
AU1083501A (en) Antibiotic-metal complex and methods